- Home
- ONFO vs ADTX Comparison
ONFO vs ADTX Comparison
Compare ONFO & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- ADTX
- Stock Information
- Founded
- ONFO 2018
- ADTX 2017
- Country
- ONFO United States
- ADTX United States
- Employees
- ONFO N/A
- ADTX N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- ADTX Health Care
- Exchange
- ONFO Nasdaq
- ADTX Nasdaq
- Market Cap
- ONFO 5.8M
- ADTX 5.3M
- IPO Year
- ONFO 2022
- ADTX 2020
- Fundamental
- Price
- ONFO $1.09
- ADTX $2.30
- Analyst Decision
- ONFO
- ADTX
- Analyst Count
- ONFO 0
- ADTX 0
- Target Price
- ONFO N/A
- ADTX N/A
- AVG Volume (30 Days)
- ONFO 57.5K
- ADTX 595.9K
- Earning Date
- ONFO 04-16-2025
- ADTX 05-19-2025
- Dividend Yield
- ONFO N/A
- ADTX N/A
- EPS Growth
- ONFO N/A
- ADTX N/A
- EPS
- ONFO N/A
- ADTX N/A
- Revenue
- ONFO $7,862,077.00
- ADTX $133,985.00
- Revenue This Year
- ONFO N/A
- ADTX $15,768.94
- Revenue Next Year
- ONFO N/A
- ADTX N/A
- P/E Ratio
- ONFO N/A
- ADTX N/A
- Revenue Growth
- ONFO 50.04
- ADTX N/A
- 52 Week Low
- ONFO $0.49
- ADTX $2.04
- 52 Week High
- ONFO $1.88
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- ONFO 51.08
- ADTX 30.49
- Support Level
- ONFO $1.05
- ADTX $2.04
- Resistance Level
- ONFO $1.14
- ADTX $2.39
- Average True Range (ATR)
- ONFO 0.09
- ADTX 0.45
- MACD
- ONFO 0.02
- ADTX 0.48
- Stochastic Oscillator
- ONFO 70.00
- ADTX 7.54
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.